Palmar Fibromatosis, also known as Dupuytren disease or Dupuytren contracture, is a benign fibroproliferative disorder in which subcutaneous fibrous nodules arise within the palmar fascia of the hand, eventually forming cordlike attachments with the adjacent flexor tendons. One of the earliest classifications of Dupuytren’s disease according to the histological appearance using optical microscopy described three stages: proliferative, involutional, and residual. The development of the condition usually occurs quite slowly over many months, or even years, though in rare cases it can develop suddenly.
Currently, there are no treatments to stop Dupuytren’s from getting worse, leaving surgery as the only viable option as the disease progresses. Surgery is considered if a finger has lost 30° of the metacarpophalangeal joint or any proximal interphalangeal joint extension. Surgery is not advocated in early Dupuytren disease except when it is associated with persistent pain, especially at night.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/palmar-fibromatosis-market
The Palmar Fibromatosis Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Palmar Fibromatosis market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Palmar Fibromatosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Palmar Fibromatosis Market Key Facts
-
According to Ball et al., (2016), the prevalence of Dupuytren’s disease in the general population increases with age, and in a recent systematic review was estimated as 12% in those aged 55 years, rising to 29% in those aged 75 years in the general population.
-
According to Walker et al. (2012), males are affected 3-4 times more often than females and the disease is more severe in men.
-
According to DelveInsight’s analysis, the older male population are affected more as compared to the older female population, in the case of Palmar Fibromatosis/Dupuytren Contracture
-
According to DiBenedetti et al. (2010), the most common first symptom that led patients to seek treatment was a hard bump (48%), followed by ropelike growth (12%), pit or dimpling (11%), and bent fingers (10%).
Key Benefits of Palmar Fibromatosis Market Report
-
Palmar Fibromatosis market report provides an in-depth analysis of Palmar Fibromatosis Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Palmar Fibromatosis Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Palmar Fibromatosis current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Palmar Fibromatosis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Palmar Fibromatosis Market
The Palmar Fibromatosis market size shall grow during the forecast period owing to the launch of novel therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Palmar Fibromatosis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Palmar Fibromatosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for Sample @ Palmar Fibromatosis Market Therapeutic Market Landscape and Key Companies
Palmar Fibromatosis Epidemiology
The epidemiology section covers insights about the historical and current Palmar Fibromatosis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Palmar Fibromatosis Epidemiology Segmentation
-
Total Prevalent Cases of Palmar Fibromatosis/Dupuytren Contracture
-
Diagnosed Cases of Palmar Fibromatosis/Dupuytren Contracture
-
Gender-specific Cases of Palmar Fibromatosis/Dupuytren Contracture
-
Age-specific Cases of Palmar Fibromatosis/Dupuytren Contracture
-
Treated Cases of Palmar Fibromatosis/Dupuytren Contracture
Palmar Fibromatosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Palmar Fibromatosis market or expected to get launched in the market during the study period. The analysis covers Palmar Fibromatosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Palmar Fibromatosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Palmar Fibromatosis market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Palmar Fibromatosis emerging therapies.
Palmar Fibromatosis/Dupuytren Contracture is not comprehensively studied, therefore, the emerging landscape of this condition is not very robust. It has been observed that very few trials had been registered for this indication. No recent development has been reported in this space except for 180 Life Sciences.
Request for Sample @ Palmar Fibromatosis Novel Therapies and Emerging Technologies
180 Life Sciences has initiated a special clinical program for preventing Duptyren’s finger and hand contracture before it becomes severe and permanent or requires surgery. 180 Life Sciences is working on Anti-TNF drug Adalimumab. Anti-TNF drug adalimumab is injected directly into the Dupuytren’s nodule tissue. 180 Life Sciences has been granted a U.S. patent for the treatment of Dupuytren’s disease, along with several other patents.
Table of Content
1. Key Insights
2. Executive Summary
3. Palmar Fibromatosis Competitive Intelligence Analysis
4. Palmar Fibromatosis Market Overview at a Glance
5. Palmar Fibromatosis Disease Background and Overview
6. Palmar Fibromatosis Patient Journey
7. Palmar Fibromatosis Epidemiology and Patient Population
8. Palmar Fibromatosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Palmar Fibromatosis Unmet Needs
10. Key Endpoints of Palmar Fibromatosis Treatment
11. Palmar Fibromatosis Marketed Products
12. Palmar Fibromatosis Emerging Therapies
13. Palmar Fibromatosis Seven Major Market Analysis
14. Attribute Analysis
15. Palmar Fibromatosis Market Outlook (7 major markets)
16. Palmar Fibromatosis Access and Reimbursement Overview
17. KOL Views on the Palmar Fibromatosis Market.
18. Palmar Fibromatosis Market Drivers
19. Palmar Fibromatosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/palmar-fibromatosis-market
Latest Reports By DelveInsight
Hypercalcemia Market
DelveInsight’s “Hypercalcemia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hypercalcemia market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/